Literature DB >> 3629187

Urinary excretion of aluminium after ingestion of sucralfate and an aluminium-containing antacid in man.

E M Haram, R Weberg, A Berstad.   

Abstract

Eleven subjects with normal renal function were given, on 2 separate days, at least 1 week apart, four tablets of sucralfate or an aluminium (Al)-containing antacid. The total Al load was approximately 976 mg with the antacid and approximately 828 mg with sucralfate. The daily urinary excretion of Al was measured the day before and during 3 days after drug administration. Al excretion increased significantly after both drugs. There was no significant difference between the two products. The median absorption calculated as percentage of Al dose was 0.005% (range, 0.001-0.017%) for sucralfate and 0.006% (range, 0.002-0.060%) for the antacid. Thus, measurable quantities of aluminium is absorbed after administration of sucralfate, and the drug should, like Al-containing antacids, be given with caution to patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3629187     DOI: 10.3109/00365528708991908

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

2.  Long-term maintenance therapy with sucralfate.

Authors:  M C Allison
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers.

Authors:  N D Priest; R J Talbot; J G Austin; J P Day; S J King; K Fifield; R G Cresswell
Journal:  Biometals       Date:  1996-07       Impact factor: 2.949

5.  The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.

Authors:  M Kamberi; H Nakashima; K Ogawa; N Oda; S Nakano
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

6.  Tissue distribution and urinary excretion of essential elements in rats orally exposed to aluminum chloride.

Authors:  J Chmielnicka; M Nasiadek
Journal:  Biol Trace Elem Res       Date:  1991-11       Impact factor: 3.738

Review 7.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 8.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

9.  Plasma and urine aluminium concentrations in healthy subjects after administration of sucralfate.

Authors:  P Allain; Y Mauras; N Krari; J Duchier; A Cournot; J Larcheveque
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

10.  Sucralfate significantly reduces ciprofloxacin concentrations in serum.

Authors:  J C Garrelts; P J Godley; J D Peterie; E H Gerlach; C C Yakshe
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.